Jan 13, 2021
J&J's one-shot Covid vaccine is safe and generates promising immune response in early trial
This news has been received from: CNBC
All trademarks, copyrights, videos, photos and logos are owned by respective news sources. News stories, videos and live streams are from trusted sources.
Johnson & Johnson Coronavirus vaccine illustrationDado Ruvic | Reuters
Johnson & Johnson's one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.
J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.
The most common side effects were fever, fatigue, headache, muscle aches and pain at the injection site, according to the trial data. Side effects were less common in the older age group, who received only one dose of the vaccine, as well as those who received a lower dose of the vaccine, according to the data.
The phase one and two clinical trial data shows a single shot of the vaccine "gives sustainable antibodies," Dr. Paul Stoffels, chief scientific officer at J&J, told CNBC's Meg Tirrell in an interview. He added it gives the company "confidence" the vaccine will be highly effective against the virus.
The trial tested 805 volunteers. The company is expected to release results from its 45,000-person phase three trial later this month. J&J is using the same technologies it used to develop its Ebola vaccine for its Covid-19 vaccine.
U.S. officials and Wall Street analysts are eagerly anticipating the authorization of J&J's vaccine, which could happen as early as next month. Public health officials and infectious disease experts say world leaders will need an array of drugs and vaccines to defeat the virus, which has killed at least 382,120 Americans since the beginning of the pandemic.
If J&J's vaccine is authorized by the Food and Drug Administration, it would be the third approved for use in the U.S. behind the Pfizer-BioNTech vaccine and Moderna's. Pfizer's vaccine was authorized on Dec. 11, and Moderna's was authorized a week later on Dec. 18.
The data comes as U.S. officials complain that the pace of vaccinations has been too slow as the supply of vaccine doses exceeds demand. The Centers for Disease Control and Prevention expanded Covid vaccine eligibility guidelines Tuesday to include people 65 and older as well as people with preexisting conditions. The government is also changing the way it allocates Covid vaccine doses, now basing it on how quickly states can administer shots and the size of their elderly population.
The Trump administration will also stop holding back millions of doses reserved for the second round of shots of Pfizer's and Moderna's two-dose vaccines, the official said, adding they've released doses that were being held in reserve on Sunday. President-elect Joe Biden's transition team announced a similar plan Friday.
Unlike Pfizer's and Moderna's authorized vaccines, which require two doses about three to four weeks apart, J&J's requires only one dose. That means patients will not have to come back for another dose, simplifying logistics for health-care providers.
The Department of Health and Human Services announced in August that it reached a deal with Janssen, J&J's pharmaceutical subsidiary, worth approximately $1 billion for 100 million doses of its vaccine. The deal gives the federal government the option to order an additional 200 million doses, according to the announcement.
Stoffels said the company plans to ship the vaccine at 2 to 8 degrees Celsius, which is about 36 to 46 degrees Fahrenheit.
"We have three months stability as of this moment at 2 to 8," he said. "That will be expanded over the year as we generate more stability data. We know from our other vaccines it can go up to a year, but at the start we can't do that because we don't have it for this vaccine."Related Tags
- Coronavirus: Prevention
- Johnson & Johnson
- Breaking News: Business
- Disease outbreaks
News Source: CNBC
Tags: coronavirus prevention breaking news business coronavirus disease outbreaks coronavirus vaccine vaccine is safe dose of the vaccine against the virus vaccine dose its vaccine million doses vaccine doses covid vaccine officials to receive vaccine authorized who received the company the company and moderna
Israel hits Hamas targets in Gaza in response to rocket fire
Israeli fighter jets struck military targets belonging to the radical Islamist movement Hamas in the Gaza Strip on Monday morning, in response to two rockets fired from the enclave, the military said in a statement. Targets included tunneling sites.
According to Hamas military sources, two military installations east of the towns of Rafah and Khan Yunis, in the southern Gaza Strip, were destroyed but no injuries were reported.
Rockets previously fired from Gaza toward the coast near the Israeli town of Ashdod were no injuries.
“The IDF (Israel Defense Forces) regards any terrorist activity against Israel with great severity and is ready to continue to operate if necessary against attempts to harm Israeli civilians or the sovereignty” of the Hebrew state, said the ‘army.
Despite a truce negotiated by Qatar between Hamas and Israel in August, several outbreaks of violence have erupted in recent months.
Israel, the United States and the European Union have placed Hamas on their respective lists of terrorist organizations.
Hamas controls the Gaza Strip, where some two million Palestinians live in conditions of overpopulation and impoverishment.
Israel has imposed a blockade there since 2007, then joined by Egypt. The two countries claim that the limits on Gazan imports are due to security reasons.